With the primary treatment for this rare disease currently just nutritional support and vitamins and supplements, NPS and Takeda could easily garner all the market share with no true competing drugs. Now what : Today we see both the boon and bane of rare-disease medicine. A lack of competition gives a company like NPS Pharmaceuticals a clear path to success in short bowel syndrome, but a lack of a large pool of patients caps the potential of the drug. The good news here is that analysts expect NPS to turn the corner to profitability in 2013, so it's quite possible this run higher could continue into next year. Craving more input? Start by adding NPS Pharmaceuticals to your free and personalized watchlist so you can keep up on the latest news with the company.